Incyte and Syndax Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host DiseasePRNewsWire • Wednesday
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)PRNewsWire • 09/06/24
Foundation Medicine Partners with Syndax to Develop a Companion Diagnostic in Hematology and Support Efforts to Pursue Regulatory Approval for an Assay Based on the FoundationOne®Heme PlatformBusiness Wire • 09/04/24
Syndax Announces Publication in the Journal of Clinical Oncology of Data from the Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute LeukemiaPRNewsWire • 08/12/24
Syndax Reports Second Quarter 2024 Financial Results and Provides Clinical and Business UpdatePRNewsWire • 08/01/24
Syndax Announces PDUFA Action Date Extension for Revumenib NDA for Relapsed or Refractory KMT2Ar Acute LeukemiaPRNewsWire • 07/29/24
Wall Street Analysts Think Syndax (SNDX) Could Surge 50.26%: Read This Before Placing a BetZacks Investment Research • 07/25/24
Syndax to Announce Second Quarter 2024 Financial Results and Host Conference Call and Webcast on August 1, 2024PRNewsWire • 07/25/24
Wall Street Analysts Believe Syndax (SNDX) Could Rally 67.11%: Here's is How to TradeZacks Investment Research • 07/09/24
Syndax Presents Updated Positive Data from BEAT AML and AUGMENT-102 Phase 1/2 Combination Trials of Revumenib in Patients with Acute Leukemias at EHA 2024 CongressPRNewsWire • 06/14/24
Syndax Announces Plans to Advance into Phase 1b Portion of Trial Evaluating Revumenib in Relapsed or Refractory Metastatic MSS CRCPRNewsWire • 06/06/24
Syndax Announces Participation at the Goldman Sachs 45th Annual Global Healthcare ConferencePRNewsWire • 06/05/24
Syndax Pharmaceuticals Appoints Aleksandra Rizo, M.D., Ph.D. to the Board of DirectorsPRNewsWire • 05/15/24
Syndax Announces Participation at the Bank of America Securities 2024 Health Care ConferencePRNewsWire • 05/09/24
Syndax Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Clinical and Business UpdatePRNewsWire • 05/08/24
Syndax to Announce First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024PRNewsWire • 05/01/24
Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology ForumPRNewsWire • 04/10/24
Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary SessionPRNewsWire • 04/08/24
Syndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid LeukemiaPRNewsWire • 03/28/24
Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute LeukemiaPRNewsWire • 03/26/24